Slide 1: AstraZeneca / Bristol-Myers Squibb Diabetes Alliance
AstraZeneca / Bristol-Myers Squibb Diabetes Alliance Becoming Global Leaders In Diabetes 2nd July 2012
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This presentation contains certain forward-looking statements
Slide 3: AstraZeneca / Bristol-Myers Squibb Diabetes Alliance
AstraZeneca / Bristol-Myers Squibb Diabetes Alliance Becoming Global Leaders In Diabetes 2nd July 2012
Slide 4: Strategic focus on diabetes
Strategic focus on diabetes • Chronic disease with many patients having Global Prevalence of Patients Diagnosed With Diabetes (m) co-morbidities (e.g. obesity, CV complications) • 366 million people had diabetes in 2011; expected to rise to 552 million by 2030 • Type 2 diabetes accounts for approx.
Slide 5: Overview of existing Diabetes Alliance with Bristol-Myers Squibb
Overview of existing Diabetes Alliance with Bristol-Myers Squibb • Collaboration established in January 2007 • Partnership to research, develop and commercialise novel drugs for Type 2 Diabetes • Shared vision dedicated to global patient care and improving patient outcomes • Portfolio includes: • On
Slide 6: Diabetes Alliance will be expanded to include Amylin's portfolio
Diabetes Alliance will be expanded to include Amylin’s portfolio • Bristol-Myers Squibb to acquire Amylin Pharmaceuticals (“Amylin”); total transaction value of ~$7 billion(1) • Following completion, AstraZeneca and Bristol-Myers Squibb will expand their existing alliance to include Amylin’s portfol
Slide 7: Strategic rationale for this deal
Strategic rationale for this deal • Creatively builds upon AstraZeneca’s and Bristol-Myers Squibb’s successful alliance in diabetes while sharing capital costs, risks and reward • Highly complementary to current portfolio by creating a more comprehensive disease management platform • Adds in-market
Slide 8: Amylin Pharmaceuticals profile
Amylin Pharmaceuticals profile • Biopharmaceutical company based in San Diego, United States • Long standing leadership in metabolics • Markets two first-in-class medicines to treat diabetes, BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection • Also marketing the first and onl
Slide 9: Amylin's Diabetes Franchise
Amylin’s Diabetes Franchise Product Indication Phase Phase 1st Weekly Diabetes Marketed Primary Care Therapy Dual-Chamber Pre-submission Pen Type 2 Diabetes Weekly Pre-phase 3 Suspension Monthly Phase 2 Completed Suspension Type 2 1st in Class Marketed Diabetes Type 1 & 1st in Class Marketed Special
Slide 10: Enhancement of existing Diabetes Alliance
Enhancement of existing Diabetes Alliance Diabetes Class Product DPP-IV Inhibitor SGLT-2 FORXIGA Inhibitor GLP-1 Receptor Agonist Amylin Analog 10
Slide 11: Driving value for AstraZeneca's shareholders
Driving value for AstraZeneca’s shareholders • Value to AstraZeneca shareholders in excess of cost of capital • Discounted cash flow valuation based; AZ and BMS independently valued the opportunity and assets, and were closely aligned • Significant revenue potential • GLP-1 class rapidly growing wit
Slide 12: Financial guidance
Financial guidance • AstraZeneca share of the alliance extension to be financed from existing cash resources and credit facilities • Initial payment ~$3.4 billion/Option payment $135 million • Timing expected third quarter 2012 following closing of acquisition of Amylin by Bristol-Myers Squibb • Gui
Slide 13: AstraZeneca / Bristol-Myers Squibb Diabetes Alliance
AstraZeneca / Bristol-Myers Squibb Diabetes Alliance Becoming Global Leaders In Diabetes 2nd July 2012